Related Experiment Video
Updated: Aug 6, 2026
09:33
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
Thoughts on carcinogenesis testing: the FDA today
1U.S. Food and Drug Administration, Rockville, Maryland 20857.
Drug Metabolism Reviews
|April 25, 2000
Summary
Future cancer prevention relies on epidemiological and animal studies to minimize exposure. New methods may reduce reliance on traditional 2-year bioassays for identifying carcinogens, aiding early cancer detection.
Area of Science:
- Toxicology
- Oncology
- Epidemiology
Background:
- Cancer prevention strategies are evolving.
- Traditional methods for identifying chemical carcinogens, like the 2-year bioassay, are being re-evaluated.
- Minimizing human exposure to carcinogens is a key goal.
Purpose of the Study:
- To discuss the future of carcinogen identification and risk management.
- To explore alternative approaches to traditional animal testing.
- To highlight the importance of understanding modes of action for carcinogen detection and early cancer diagnosis.
Main Methods:
- Review of current trends in animal testing and research.
- Discussion of epidemiological and animal study findings.
- Exploration of alternative markers for carcinogenic potential.
Main Results:
- Changes in animal testing suggest reduced dependence on 2-year bioassays for initial screening.
- Understanding the mode of action of chemicals can improve carcinogen identification.
- New markers may aid in early cancer detection.
Conclusions:
- Future cancer prevention will integrate epidemiological data, animal studies, and exposure minimization.
- The 2-year bioassay may shift from a primary screening tool to a confirmatory method.
- Describing modes of action is crucial for predicting carcinogenic potential and enabling early cancer detection.
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
Related Concept Videos
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...